DelveInsight’s, “Huntington’s Disease Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Huntington’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Huntington’s Disease Pipeline treatment landscape of the report, click here @ Huntington’s Disease Pipeline Outlook
Key takeaways from the Huntington’s Disease Pipeline Report
Got Queries? Find out the related information on Huntington’s Disease Mergers and acquisitions, Huntington’s Disease Licensing Activities @ Huntington’s Disease Emerging Drugs, and Recent Trends
Huntington’s Disease Overview
Huntington’s disease is a rare, inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain. It is an autosomal dominant disorder caused by a single defective gene on chromosome 4. The symptoms of Huntington’s Disease include involuntary jerking or writhing movements (chorea), muscle problems, such as rigidity or muscle contracture (dystonia), slow or abnormal eye movements, impaired balance, difficulty with speech or swallowing, difficulty organizing, prioritizing or focusing on tasks, and/or fatigue and loss of energy. A diagnosis of Huntington’s disease is based upon a general physical examination, medical history, and thorough neurological and psychiatric examinations. Treatment for Huntington’s disease is focus on managing the symptoms of the disease, includes medications and psychotherapy. Tetrabenazine (Xenazine) and deutetrabenazine (Austedo), which have been specifically approved by the FDA to suppress the involuntary jerking and writhing movements (chorea) associated with Huntington’s disease.
Latest Developmental Activities or News of the Huntington’s Disease Treatment Landscape
For further information, refer to the detailed Huntington’s Disease Unmet Needs, Huntington’s Disease Market Drivers, and Huntington’s Disease Market Barriers, click here for Huntington’s Disease Ongoing Clinical Trial Analysis
Huntington’s Disease Emerging Drugs Profile
Pridopidine: Prilenia Therapeutics
Pridopidine is a highly selective, first in class small molecule which is sigma-1 receptor (S1R) agonist. Pridopidine is currently in late-stage clinical development for Huntington’s disease. Prilenia has an orphan drug designation for pridopidine for the treatment of Huntington’s disease in both the US and Europe.
Tominersen: Ionis Pharmaceuticals
Tominersen (formerly known as IONIS-HTTRx and RG6042) is an investigational antisense medicine designed to reduce the production of the huntingtin (HTT) protein, which is the genetic cause of Huntington’s disease (HD). The US FDA granted orphan drug designation to Ionis Pharmaceuticals, for tominersen for the treatment of Huntington’s disease in January 2016. In August 2018, European Medicines Agency (EMA) granted PRIME (PRIority MEdicines) designation for the tominersen for the treatment of Huntington’s disease (HD). Ionis Pharmaceuticals entered into a collaboration with Roche to develop and commercialize antisense medicines to treat HD in April 2013.
Huntington’s Disease Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Huntington’s Disease. The companies which have their Huntington’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.
Request a sample and discover the recent advances in Huntington’s Disease Ongoing Clinical Trial Analysis and Medications, click here @ Huntington’s Disease Treatment Landscape
Scope of the Huntington’s Disease Pipeline Insight Report
Dive deep into rich insights for drugs for Huntington’s Disease Market Drivers and Huntington’s Disease Market Barriers, click here @ Huntington’s Disease Unmet Needs and Analyst Views
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting